Podcast Video: GLP 1, Mounjaro & Ozempic: How These Affect Weight Loss & Metabolic Health with Dr. Robert Lustig
This podcast episode was originally published on August 17, 2023.
Medications, such as Ozempic, Mounjaro, Wegovy, and more, have become increasingly popular for weight loss. These drugs are glucagon-like peptide 1 (GLP-1) receptor agonists, and they mimic a hormone that, among other things, tells the brain a person is full so they eat less. But are they safe, and do they help improve metabolic health? Dr. Rob Lustig and Dr. Casey Means discuss these weight-loss drugs and their effects on the body, and why such medications likely won’t solve the obesity crisis, for which the food industry is culpable.
What we discuss:
The mechanisms of action for weight-loss medications
Dr. Casey Means shares her perception of the popularity of GLP-1 medications
GLP-1 RAs lead to fat loss but also muscle loss
Do GLP-1 RAs improve metabolic health?
Dr. Lustig discusses the high cost of GLP-1 RAs
Dr. Lustig makes the case for fixing the food problem
How can patients use GLP-1 RAs as a jumpstart?
Dr. Lustig shares his concerns about the use of GLP-1 RAs in children
